Skip to Content

Zevalin (ibritumomab) Disease Interactions

There are 3 disease interactions with Zevalin (ibritumomab):

Major

Ibritumomab tiuxetan (applies to Zevalin) cytopenia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve. It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.

Major

Ibritumomab tiuxetan (applies to Zevalin) vaccination

Major Potential Hazard, Moderate plausibility.

The safety of immunization with live viral vaccines following the ibritumomab tiuxetan has not been studied. Do not administer live viral vaccines to patients who have recently received ibritumomab tiuxetan. The ability to generate an immune response to any vaccine following the therapeutic regimen has not been studied.

Moderate

Ibritumomab tiuxetan (applies to Zevalin) hematological toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Myelodysplastic Disease, Leukemia

The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.

Zevalin (ibritumomab) drug interactions

There are 237 drug interactions with Zevalin (ibritumomab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.